Rheumatology Grand Rounds

*Presented by*

Section of Rheumatology, Allergy & Immunology

**“Rheumatic Complications of Immune**

**Checkpoint Inhibition”**

Nilasha Ghosh, MD

Rheumatology Fellow, Hospital for Special Surgery

**Date: Wednesday, June 2, 2021 ~ Time: 8:00-9:00 am**

ZOOM: <https://zoom.us/j/95472436781?pwd=bVpyZ2NueGpJbjR1TjVsMjhKZDBUQT09&from=addon>

Meeting ID: 954 7243 6781

CME: Text the code 20708 to 203-442-9435 from 7:45am-9:15am

**Course Director/Host: Fotios Koumpouras, MD**

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE**

Department faculty, attending physicians, subspecialty fellows, community physicians, resident house staff, physician assistants and medical students.

**NEEDS ASSESSMENT**

Immune checkpoint inhibitors are a widely used type of cancer immunotherapy and can cause immune-related adverse events (irAEs). Immune activation and inflammation induced by IrAEs can affect multiple organ systems. Rheumatologic irAEs include arthralgia, myalgia, and sicca complex most commonly, as well as systemic disease such as inflammatory arthritis, myositis, Sjögren's syndrome, or vasculitis less commonly. Patients with preexisting autoimmune diseases can experience flares of their disease or development a different autoimmune disease. Dr. Nilasha Ghosh will discuss how to recognize different clinical presentations of checkpoint inhibitor associated arthritis and myositis, will describe similarities and differences between rheumatic complications of checkpoint inhibitors and traditional rheumatic diseases, and lastly will discuss current and future trends in checkpoint inhibitor research within rheumatology.

**LEARNING OBJECTIVES**

At the conclusion of this activity, participants will be able to:

1. Recognize different clinical presentations of checkpoint inhibitor associated arthritis and myositis

2. Describe similarities and differences between rheumatic complications of checkpoint inhibitors and traditional rheumatic diseases

3. Discuss current and future trends in checkpoint inhibitor research within rheumatology

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES**

*Speaker:* Nilasha Ghosh, MD – NONE

*Course Director:* Fotios Koumpouras, MD- Celgene (honorarium), Aurora (research grant), EMD, ULB, GSK (research grant)

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.